Salarius Pharmaceuticals, Inc. - SLRX STOCK NEWS

Salarius Pharmaceuticals (Nasdaq: SLRX) has announced a transformative acquisition of a targeted protein degradation portfolio from DeuteRx, significantly enhancing its oncology pipeline. The acquisition includes the lead candidate SP-3164 (formerly DRX-164), which is set to enter clinical trials in 2023. Salarius aims to develop this candidate and additional assets targeting previously undruggable cancer-promoting proteins. The agreement involves an upfront payment of $1.5 million and shares, with potential future payments totaling up to $188 million based on milestones.

Salarius Pharmaceuticals will present at H.C. Wainwright BioConnect and participate in Biotech Showcase and BIO Partnering @ JPM, all virtually alongside the 40th Annual Healthcare Conference 2022. Key dates include Biotech Showcase from January 10-12, H.C. Wainwright BioConnect from January 10-13, and BIO Partnering @ JPM from January 10-14. CEO David Arthur will deliver a presentation on seclidemstat, Salarius' investigational drug for pediatric and other cancers. Salarius has received FDA designations for Ewing sarcoma and aims to expand its clinical trials in cancers with high unmet needs.

Salarius Pharmaceuticals (Nasdaq: SLRX) has achieved a significant milestone by advancing the Ewing sarcoma arm of its Phase 1/2 Sarcoma trial to a second lead-in safety cohort. Patients in this cohort will receive a combination of seclidemstat, topotecan, and cyclophosphamide at a 900 mg BID dosage. The trial aims to assess the safety and efficacy of seclidemstat for relapsed/refractory Ewing sarcoma and FET-rearranged sarcomas. Currently, 13 clinical trial sites are actively enrolling patients, with anticipated data readouts in 2022.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the Life Science Investor Forum on December 16, 2021. The presentation will cover the company's recent achievements and future milestones related to seclidemstat, a drug in clinical trials for Ewing sarcoma and hematologic cancers. The Phase 1/2 trials are assessing seclidemstat with chemotherapy agents and azacytidine. Investors can register for the event, which will be streamed live, and a recording will be available afterward on the company's website.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced participation in the Benchmark Company Discovery One-on-One Investor Conference on December 2, 2021. CEO David Arthur and the management team will engage in one-on-one meetings with registered investors to discuss the company’s business highlights, recent achievements, and upcoming clinical milestones. Salarius is focused on developing novel therapies for cancers, particularly its lead candidate, seclidemstat, which is in clinical trials for Ewing sarcoma and related cancers.

Salarius Pharmaceuticals (SLRX) reported a net loss of $3.7 million or $0.08 per share for Q3 2021, an increase from $1.7 million in the same period last year. The total working capital stood at $33.6 million, bolstered by a $2.7 million disbursement from CPRIT. The company is progressing with clinical trials for its lead drug candidate, seclidemstat, with 13 active sites now supporting enrollment. The Ewing sarcoma safety lead-in cohort is fully enrolled, and seclidemstat's development pipeline is expanding with new collaborations and clinical sites.

Salarius Pharmaceuticals (Nasdaq: SLRX) will host a conference call on November 4, 2021, at 5:00 p.m. ET to discuss its corporate and financial results for Q3 2021. The call can be accessed via phone or online, with an archive available for 90 days post-event. Salarius is focused on developing treatments for cancers with high unmet medical needs, including their lead candidate, seclidemstat, currently in clinical trials for Ewing sarcoma and other cancers. The company has received multiple designations from the FDA, highlighting its commitment to advancing oncology treatments.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) presented significant preclinical findings at the 2021 AACR-NCI-EORTC Conference, focusing on its lead drug candidate, seclidemstat (SP-2577). The research highlights seclidemstat's unique action against FET-rearranged sarcomas, showcasing potent activity in preclinical models, especially in Ewing sarcoma and desmoplastic small round cell tumors. The data suggests seclidemstat's differentiated mechanism exceeds other LSD1 inhibitors, leading to a strategic amendment in its ongoing Phase 1/2 trial to include FET-rearranged sarcoma patients. Further studies aim to identify biomarkers for treatment sensitivity.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present virtually at the 2021 BioFuture Conference on October 5-6 in New York City. His presentation will cover the company's clinical achievements and future milestones for seclidemstat, an oral LSD1 inhibitor. Seclidemstat is undergoing a Phase 1/2 trial for Ewing sarcoma and another trial for hematologic cancers. Interested investors can register here. A recording will later be available on the company's website.